Stay updated with breaking news from Sys Group Key Figures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim StatementMorphoSys AG Reports First Quarter 2024 Financial Results 29.04.2024 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, April 29, 2024 MorphoSys AG Reports First Quarter 20...
MorphoSys AG reports results for the first quarter of 2024. "The proposed acquisition by Novartis is advancing steadily, and we continue to anticipate its closure in the first half of 2024. The acceptance period for the acquisition is currently...
EQS-News: MorphoSys AG / Key word: Annual Report MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update 13.03.2024 / 21:01...
EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim StatementMorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results 15.11.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, November 15, 2023 MorphoSys AG...
Monjuvi U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023 Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline